| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
§
From the Department of Medical Cell Biology,*
Biomedical
Centre, Uppsala University, Uppsala; the Departments of Women and Child
Health
and Surgery,
Children's Academic Hospital, Uppsala, and the Departments of Genetics
and Pathology §
and Medical
Sciences,¶
University Hospital,
Uppsala, Sweden
Inhibition of angiogenesis has been shown to reduce tumor growth, metastasis, and tumor microvascular density in experimental models. To these effects we would now like to add induction of differentiation, based on biological analysis of xenografted human neuroblastoma (SH-SY5Y, WAG rnu/rnu) treated with the angiogenesis inhibitor TNP-470. Treatment with TNP-470 (10 mg/kg s.c., n = 15) reduced the tumor growth by 66% and stereological vascular parameters (LV, VV, SV) by 3645%. The tumor cell apoptotic fraction increased more than threefold, resulting in a decrease in viable tumor cells by 33%. In contrast, the mean vascular diameter (29 µm) and the mean tumor cell proliferative index (49%) were unaffected. TNP-470-treated tumors exhibited striking chromaffin differentiation of neuroblastoma cells, observed as increased expression of insulin-like growth factor II gene (+ 88%), tyrosine hydroxylase (+ 96%), chromogranin A, and cellular processes. Statistical analysis revealed an inverse correlation between differentiation and angiogenesis. It is suggested that by inhibiting angiogenesis, TNP-470 induces metabolic stress, resulting in chromaffin differentiation and apoptosis in neuroblastoma. Such agonal differentiation may be the link between angiostatic therapy and tumor cell apoptosis.
This article has been cited by other articles:
![]() |
C. Brignole, D. Marimpietri, F. Pastorino, B. Nico, D. Di Paolo, M. Cioni, F. Piccardi, M. Cilli, A. Pezzolo, M. V. Corrias, et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst, August 16, 2006; 98(16): 1142 - 1157. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Hsu, F. J. Hsieh, Y. M. Jeng, M. L. Kuo, C. N. Chen, D. M. Lai, L. J. Hsieh, B. T. Wang, P. N. Tsao, H. Lee, et al. Calreticulin expression in neuroblastoma--a novel independent prognostic factor Ann. Onc., February 1, 2005; 16(2): 314 - 321. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Furuhashi, T. Sjoblom, A. Abramsson, J. Ellingsen, P. Micke, H. Li, E. Bergsten-Folestad, U. Eriksson, R. Heuchel, C. Betsholtz, et al. Platelet-Derived Growth Factor Production by B16 Melanoma Cells Leads to Increased Pericyte Abundance in Tumors and an Associated Increase in Tumor Growth Rate Cancer Res., April 15, 2004; 64(8): 2725 - 2733. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-K. Olsson, H. Larsson, J. Dixelius, I. Johansson, C. Lee, C. Oellig, I. Bjork, and L. Claesson-Welsh A Fragment of Histidine-Rich Glycoprotein Is a Potent Inhibitor of Tumor Vascularization Cancer Res., January 15, 2004; 64(2): 599 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Wachsberger, R. Burd, and A. P. Dicker Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interaction Clin. Cancer Res., June 1, 2003; 9(6): 1957 - 1971. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Trager, P. Kogner, M. Lindskog, F. Ponthan, A. Kullman, and B. Kagedal Quantitative Analysis of Tyrosine Hydroxylase mRNA for Sensitive Detection of Neuroblastoma Cells in Blood and Bone Marrow Clin. Chem., January 1, 2003; 49(1): 104 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Pietras, K. Rubin, T. Sjoblom, E. Buchdunger, M. Sjoquist, C.-H. Heldin, and A. Ostman Inhibition of PDGF Receptor Signaling in Tumor Stroma Enhances Antitumor Effect of Chemotherapy Cancer Res., October 1, 2002; 62(19): 5476 - 5484. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sjoblom, A. Shimizu, K. P. O'Brien, K. Pietras, P. Dal Cin, E. Buchdunger, J. P. Dumanski, A. Ostman, and C.-H. Heldin Growth Inhibition of Dermatofibrosarcoma Protuberans Tumors by the Platelet-derived Growth Factor Receptor Antagonist STI571 through Induction of Apoptosis Cancer Res., August 1, 2001; 61(15): 5778 - 5783. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Larsson, T. Sjöblom, J. Dixelius, A. Östman, K. Ylinenjärvi, I. Björk, and L. Claesson-Welsh Antiangiogenic Effects of Latent Antithrombin through Perturbed Cell-Matrix Interactions and Apoptosis of Endothelial Cells Cancer Res., December 1, 2000; 60(23): 6723 - 6729. [Abstract] [Full Text] |
||||
![]() |
C.-G. Lee, M. Heijn, E. di Tomaso, G. Griffon-Etienne, M. Ancukiewicz, C. Koike, K. R. Park, N. Ferrara, R. K. Jain, H. D. Suit, et al. Anti-Vascular Endothelial Growth Factor Treatment Augments Tumor Radiation Response under Normoxic or Hypoxic Conditions Cancer Res., October 1, 2000; 60(19): 5565 - 5570. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |